Denifanstat’s long-term safety profile in acne was clean in Ascletis’ open-label Phase 3 extension: among 240 patients treated once daily for up to 40 weeks (52 weeks total exposure for those previously on drug), only two treatment-emergent adverse event categories reached 5% incidence—dry eye (5.5%) and dry skin (5.2%). All denifanstat-related adverse events were mild or moderate, with no related Grade 3/4 events, no adverse event–related discontinuations, one case of Grade 1 hair thinning that resolved on treatment, no denifanstat-related serious adverse events, and two unrelated SAEs that resolved. Efficacy measures improved beyond 12 weeks across IGA response and lesion count reductions, though quantitative data were not released.
The core update is a positive topline from the multicenter Phase 3 open-label safety study (ASC40-304) in moderate to severe acne, following a 480-patient randomized, double-blind Phase 3 (ASC40-303) that met all primary and secondary endpoints at 12 weeks in mid-2025. Denifanstat (ASC40) is an oral fatty acid synthase inhibitor licensed by Sagimet to Ascletis for acne in China; Sagimet is advancing the same molecule globally in MASH. The extension was designed to establish chronic tolerability—a pivotal requirement for an oral therapy in a largely adolescent and young adult population where sustained treatment is common.
Strategically, this is a China-first dermatology play that leverages local execution to accelerate late-stage validation while Sagimet pursues metabolic liver indications ex-China. The absence of serious drug-related toxicities over nearly a year of exposure positions FASN inhibition as a potentially scalable systemic mechanism in a category long dominated by agents with either teratogenicity and monitoring burdens or limited efficacy ceilings. For Sagimet, the dermatology safety narrative de-risks class effects ahead of broader exposure in MASH and a planned combination path with resmetirom in cirrhosis, offering cross-indication safety optionality that could ease regulatory dialogue and site onboarding. The tension is that today’s efficacy signal remains qualitative; until the magnitude and durability of response are disclosed, claims of differentiation versus isotretinoin, hormonal approaches, and newer androgen-targeted therapies will be provisional.
For sites and CROs, the tolerability profile suggests fewer discontinuations and a lighter safety monitoring load, which can stabilize retention and reduce operational friction in long-duration acne studies. In China, dermatology networks and vendors focused on longitudinal adherence and remote visit logistics may see increased demand as sponsors shift toward chronic oral regimens with year-long follow-up windows. Sponsors outside China will parse whether this dataset can inform safety assumptions and protocol design for systemic FASN programs in both dermatology and metabolic disease, especially around AE adjudication, patient-reported dryness assessments, and reproductive risk management frameworks. Regulators gain extended-exposure data in a youthful population, narrowing uncertainty around systemic effects of FASN inhibition.
Next, watch for the full data cut: quantitative IGA 0/1 rates, ≥2-grade shifts, and inflammatory/total lesion percentage reductions at 24–52 weeks, plus lab panels capturing hepatic, lipid, and ophthalmic signals. Ascletis’ NMPA filing timing will indicate confidence in the dataset’s sufficiency as a long-term safety package paired with the prior randomized efficacy readout. Any head-to-head or active-controlled plans would clarify positioning against entrenched standards. For Sagimet, updates on manufacturing scale-up and the second FASN inhibitor (TVB-3567) in acne, alongside MASH regulatory interactions, will signal whether the class can support multi-indication commercialization. The principal risk is interpretability: open-label efficacy without numbers, regional conduct, and the absence of detailed laboratory safety data leave gaps that the upcoming congress presentations will need to fill.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
